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Abstract
In order to improve knowledge on Escherichia coli bacteraemia during pregnancy, we studied clinical data and performed molecular
characterization of strains for 29 E. coli bacteraemia occurring in pregnant women. Bacteraemia mostly occurred in the third trimester of
pregnancy (45%) and was community-acquired (79%). Portals of entry were urinary (55%) and genital (45%). E. coli strains belonged mainly
to phylogroups B2 (72%) and D (17%). Four clonal lineages (i.e. sequence type complex (STc) 73, STc95, STc12 and STc69) represented 65%
of the strains. The strains exhibited a high number of virulence factor coding genes (10 (3–16)). Six foetuses died (27%), five of them due to
bacteraemia of genital origin (83%). Foetal deaths occurred despite adequate antibiotic regimens. Strains associated with foetal mortality had
fewer virulence factors (8 (6–10)) than strains involved in no foetal mortality (11 (4–12)) (p 0.02). When comparing E. coli strains involved in
bacteraemia with a urinary portal of entry in non-immunocompromised pregnant vs. non-immunocompromised non-pregnant women from
the COLIBAFI study, there was no significant difference of phylogroups and virulence factor coding genes. These results show that E. coli
bacteraemia in pregnant women involve few highly virulent clones but that severity, represented by foetal death, is mainly related to
bacteraemia of genital origin.
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Introduction
Bacterial infections during pregnancy remain a relevant com-
plication, even in developed countries [1]. Sepsis is now the
most common cause of direct maternal death [2], with 1.1
maternal deaths for 100 000 pregnancies in the UK between
2006 and 2008. The incidence of bacteraemia during pregnancy
varies from 3 to 7.5 for 1000 pregnancies [3,4]. Bacteraemia
during pregnancy is also life-threatening for fetuses, with 10%
of foetal death in a retrospective study [4].
Escherichia coli is one of the most common organisms
involved in bacteraemia in the general population [5,6] and
during pregnancy [3,4,7–10]. This bacterium was involved in
44% of bacteraemia during pregnancy in a recent study by
Surgers et al. [4]. The E. coli species is classified in at least
seven phylogenetic groups (A, B1, B2, C, D, E and F) [11].
Classically, extra-intestinal virulent strains belong to phylo-
groups B2 and, to a lesser extent, D [12]. The intrinsic
virulence of the strains, assessed in a mouse model of sepsis, is
mostly determined by the presence of virulence genes [12].
However, the contribution of these bacterial determinants of
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E. coli to patient mortality was found to be low regarding host
factors or portal of entry in a prospective study of E. coli
bacteraemia in adults [13]. Because little is known about E. coli
bacteraemia in pregnant women, we conducted a study to
describe clinical and microbiological characteristics of bacter-
aemia during pregnancy and to compare clinical and bacterial
characteristics of bacteraemia: (i) according to the portal of
entry, (ii) according to the severity of bacteraemia evaluated by
foetal mortality, and (iii) in pregnant women vs. non-pregnant
women with a urinary portal of entry.
Materials and Methods
Studied patients
This analysis focused on pregnant women with E. coli bacter-
aemia included in two previous studies. The first one was the
multicentre prospective COLIBAFI study [13]. This study
enrolled 1051 adults with E. coli bacteraemia and was carried
out in France between January 2005 and November 2007. The
second study was a multicentre retrospective study of
bacteriaemic pregnant women conducted in France between
2005 and 2009 [4]. Women were included until 7 days
post-delivery. All E. coli strains were centralized in one
laboratory (INSERM, UMR 1137) for molecular epidemiolog-
ical studies.
For the case-control analysis, cases were non-immunocom-
promised pregnant women with a urinary portal of entry. Each
case was matched to two controls. Controls were chosen
from the original COLIBAFI cohort [13]. Eligible controls were
non-pregnant women aged from 18 to 51 years, who had a
urinary portal of entry of bacteraemia and were not immu-
nocompromised. Patients were matched for age using a greedy
algorithm (http://mayoresearch.mayo.edu).
Clinical data
The following demographic characteristics and underlying
conditions were collected: age, place of birth, antibiotherapy
within 2 weeks, tobacco addiction, diabetes including gesta-
tional diabetes and history of previous bacteraemia. Patients
were considered to be immunocompromised if they had at
least one of the following conditions: solid or bone-marrow
transplantation, immunosuppressive therapy, solid cancer,
haemopathy and HIV infection.
The portal of entry of bacteraemia was established after
review of each medical record conjointly by obstetricians and
infectious disease specialists through a careful evaluation of all
possible sources according to clinical and microbiological
features (i.e. E. coli had to be isolated in the blood culture and
in the sample from the presumed source of bacteraemia).
Bacteraemia episodes were classified according to the
gestational age at occurrence: first trimester (T1) (before
15 weeks’ gestation), second trimester (T2) (between 15
and 28 completed weeks’ gestation), third trimester (T3)
(after 28 weeks’ gestation) and post-partum until 7 days
post-delivery (PP). They were considered to be
community-acquired if the first positive blood culture was
obtained within the first 48 h after admission. All patients
were followed-up until hospital discharge (up to 28 days
maximum).
Bacterial strains
Strains were conserved with glycerol shortly after isolation
and stored at 80°C. Genomic DNA was extracted using
the WIZARD DNA genomic kit from Promega (Madison,
WI, USA). All strains were characterized in terms of
phylogenetic group with the new quadruplex PCR method,
which allows the delineation of the seven main phylogenetic
groups [11]. Ten main B2 phylogenetic subgoups (I–X) were
detected by allele-specific PCRs [14,15]. They correspond to
clonal lineages or sequence type complexes (STc) 131, 73,
127, 141, 144, 12, 14, 452, 95 and 372, respectively,
according to the Achtman multilocus sequence typing
(MLST) scheme [16]. Among the D phylogroup strains,
clonal group A (CGA), which corresponds to STc69, was
identified as previously described [17]. O-types were
determined by allele-specific PCR or by the classical
serological method when necessary [18]. PCR was used to
detect the presence of genes encoding 18 virulence factors,
including adhesins (papC, papG, including papG alleles, sfa/foc,
iha, hra and ibeA), toxins (hlyC, cnf1 and sat), iron capture
systems (fyuA, irp2, iroN, iucC and ireA), protectins (neuC,
chromosomal ompT and traT) and usp, a gene encoding for a
uropathogenic-specific protein. Virulence factors were clus-
tered on genomic islands called pathogenicity-associated
islands (PAIs) as in Lefort et al. [13].
Antimicrobial susceptibilities were determined for 18
antibiotics with the disk-diffusion method with Mueller-
Hinton agar, as recommended by Comite de l’Antibiogram
me de la Societe Francaise de Microbiologie standards
(www.sfm-microbiologie.org). A strain was considered to be
multidrug resistant if it was resistant to amoxicillin, ofloxacin
and cotrimoxazole. For each strain, a resistance score was
computed as the number of antibiotics to which it was
resistant among the following: amoxicillin, cefotaxime,
gentamicin, ofloxacin and cotrimoxazole [13]. The empirical
antimicrobial therapy was considered to be adequate if
the results of susceptibility testing revealed that the isolate
was susceptible to the empirical antimicrobial therapy
prescribed.
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Statistical analysis
We first performed a descriptive analysis. Descriptive statistics
were expressed as number and percentage and as median and
interquartile range, as appropriate. We then performed a
univariate comparison of clinical and bacterial characteristics
for urinary vs. genital portal of entry of bacteraemia. Clinical
characteristics studied included immunosuppression, antibiotic
treatment within 2 weeks before the diagnosis of bacteraemia,
tobacco addiction, diabetes mellitus, a previous history of
bacteraemia, nosocomial bacteraemia and adequacy of empir-
ical antibiotics. Bacterial characteristics included resistance to
the 18 antibiotics tested, resistance score, multidrug resis-
tance, phylogroup (for simplicity, the only F strain was
considered to belong to the D phylogroup as it appears D
using the triplex PCR phylogrouping method) [11] and
presence of 18 virulence genes with characterization of six
PAIs.
A second univariate analysis was performed to analyse the
factors associated with foetal death. We performed this
comparison in bacteraemia occurring during pregnancy, and
post-partum bacteraemia were excluded. We analysed the
same clinical and bacterial characteristics as those used above
in the first univariate analysis. Comparisons between groups
were performed using the non-parametric Wilcoxon or
Fisher’s exact tests, as appropriate.
We finally performed a matched case-control analysis to
identify factors associated with E. coli bacteraemia during
pregnancy using a univariate conditional logistic regression.
The same clinical and bacterial characteristics as in previous
analyses were studied.
All analyses were performed with SAS v9.3 (SAS Institute
Inc., Cary, NC, USA). All tests were two-sided with a type-I
error fixed to 0.05.
Results
Global clinical characteristics
Twenty-nine women with E. coli bacteraemia during pregnancy
and the early postpartum (PP) period were included (Table 1).
Fourteen patients were from the COLIBAFI cohort, and 15
women were included from the retrospective study. The
median age was 31(20–46) years. One patient was considered
to be immunocompromised because she was receiving a
long-term corticosteroid treatment (prednisone 10 mg/day)
for an unknown reason. Bacteraemia mostly occurred during
the third trimester (n = 13, 45%). Seven bacteraemias
occurred postpartum (24%). Gestational age of occurrence
was unknown for two patients. Bacteraemia was mostly
community-acquired (n = 23, 79%). Two portals of entry were
reported: urinary tract infections (n = 16, 55%) and genital
tract infections (chorioamnionitis during pregnancy and endo-
metritis PP) (n = 13, 45%). No maternal death was observed
during the period of sepsis or up till day 28. Nevertheless, two
pregnant non-immunocompromised women were transferred
to the intensive care unit (ICU) for septic shock due to genital
tract infections (i.e. chorioamnionitis) occurring during T1/T2
of pregnancy.
Among the 22 bacteraemias occurring during pregnancy, six
foetuses died (27%). Five out of the six foetal deaths occurred
in a context of chorioamnionitis following preterm prelabour
rupture of the membranes. No neonates died and global
mortality associated with bacteraemia during pregnancy and
the early post-partum period was 21%.
Bacterial strain characteristics
The 29 E. coli strains are described in Table 2. Twenty-one
belonged to the B2 phylogroup (72%), five to the D
phylogroup (17%), five to the A phylogroup (7%) and one to
phylogroup F (3%). Among the B2 group strains, seven
belonged to B2 subgroup II (33%), four to subgroup IX
(19%), four to subgroup VI (19%), three to subgroup I (14%)
and two to subgroup IV (10%), whereas only one strain was
unassignable to any subgroup tested (5%). All except one D
strain belonged to the CGA clone (80%). We observed 14
different O-types. Most represented O-types were O6a
(n = 8, 28%), O4 (n = 4, 14%) and O1 (n = 3, 10%). The
median virulence score was 10 (3–16). The frequency of PAIs
ranged from 10% for PAIgimA to 90% for PAIIV536, with values of
TABLE 1. Clinical characteristics of the 29 pregnant women
with E. coli bacteraemia
Demographics
Age in years median (range) 31 (20–46)
n (%)
Place of birth
Europe 15 (51.7)
Africa 9 (31.0)
Asia 1 (3.5)
Unknown 4 (13.8)
Clinical
Immunosuppression 1 (3.5)
Antibiotics within 2 weeks 1 (3.5)
Tobacco addiction 5 (17.2)
Diabetes 4 (13.8)
Previous bacteraemia 1 (3.5)
Community-acquired bacteraemia 23 (79.3)
Empirical antibiotic inadequate 8 (28.6)
Foetal death 6 (20.7)
ICU admission for mother 2 (6.9)
Portal of entry
Urinary tract 16 (55.2)
Genital tract 13 (44.8)
Gestational age at the time of bacteraemia
First trimester 1 (3.5)
Second trimester 6 (20.7)
Third trimester 13 (44.8)
Unknown 2 (6.9)
Post-partum 7 (24.1)
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21%, 34%, 41% and 72% for PAIICFT073, PAIIIJ96, PAIIII536 and
PAIUSP, respectively.
Eighteen strains were resistant to amoxicillin (62%) and 14
to amoxicillin-clavulanate (48%). No strain exhibited
extended-spectrum b-lactamase (ESBL) and one strain (3%)
was resistant to quinolones (i.e. nalidixic acid, ofloxacin and
ciprofloxacin). The median resistance score was 1 [0–3]) and
one strain was multidrug resistant (3%). Antibiotic therapy was
inadequate for eight patients (28%), consisting of an initial
prescription of amoxicillin or amoxicillin-clavulanate.
Portal of entry
No significant difference was observed between urinary and
genital portals of entry for bacteraemia in terms of host
characteristics, nosocomial/community-acquired infection, tri-
mester of occurrence and bacterial characteristics.
Severity of mother sepsis and foetal death
Of the 29 patients included, two were transferred to the ICU
during hospitalization. Neither of these two women was
immunocompromised. Empirical antibiotic therapy was not
adapted for one patient; the second patient lost the foetus.
Both isolated strains belonged to the B2 phylogroup, with a
virulence score of 12 and 8, respectively.
Among the six foetal deaths due to the 22 bacteraemias
occurring during pregnancy, five were observed in patients
with a genital portal of entry (83%) and one observed in a
patient with a urinary portal of entry (17%) (p 0.06). When
comparing bacterial characteristics according to the occur-
rence of foetal death, no significant difference in phylogenetic
group and antimicrobial susceptibility profile was observed.
However, virulence score was significantly higher in the group
of surviving foetuses than in the group with foetal death (11
[4–12] vs. 8 [6–10], p 0.02). Strains associated with foetal
death carried less frequently the papC or papG genes (p 0.04
for both virulence factor genes). Empirical antibiotic therapy
was adapted due to susceptibility testing for all bacteraemias
associated with foetal death (6/6, 100%) but not adapted for
seven of the 16 patients without foetal death (44%) (p 0.05)
(Table 3).
Comparison of bacteraemia in pregnant and non-pregnant
women
Among the 29 pregnant women included in this analysis, 16
had a urinary portal of entry, one of whom was immunocom-
promised. Fifteen pregnant women were thus matched to 30
controls from the COLIBAFI study. No significant difference
was observed between cases and controls for any of the
clinical or bacterial characteristics studied in the univariate
case control analysis (Table 4).
Discussion
We report here the results of the largest study ever published
focusing on E. coli bacteraemia during pregnancy, a rare but
severe event [4]. Bacteraemia occurred mostly during T3 and
was mostly community acquired. No maternal death was
observed. The most remarkable result of our study is the very
TABLE 2. Phylogroups and subgroups, O-type, virulence and
resistance scores of the 29 E. coli strains isolated from
pregnant women
Strain ID Phylogroup
Clonal
groupa O type
Virulence
score
Resistance
score
R1B6F18 A / O77 8 0
HFE7 A A1 O6a 4 1
HFE3C B2 B2-I O120 8 2
HFE2 B2 B2-I O25b 8 2
R1B5C13 B2 B2-I O6a 9 1
R1B4E1 B2 B2-II O22 9 0
R1B9C4 B2 B2-II O4 6 0
HFE10 B2 B2-II O6a 10 2
HFE12 B2 B2-II O6a 16 2
HFE15 B2 B2-II O6a 11 2
HFE8 B2 B2-II O6a 15 0
R1B12B17 B2 B2-II O6a 12 1
HFE1 B2 B2-IV O2b 12 0
HFE5 B2 B2-IV O2b 9 2
HFE11 B2 B2-IX O1 10 1
R1B3J4 B2 B2-IX O1 15 0
R1B4F3 B2 B2-IX O1 12 0
R1B8D18 B2 B2-IX O2a 10 1
HFE16 B2 B2-UA O75 12 0
R1B6E1 B2 B2-VI O21 11 1
HFE9 B2 B2-VI O4 12 1
R1B1G3 B2 B2-VI O4 13 1
R1B6J15 B2 B2-VI O4 13 1
R1B6G4 D / O7 3 0
R1B13H4 D CGA O17 3 1
HFE6 D CGA O6a 9 2
R1B5D10 D CGA O73 6 1
HFE4 D CGA O77 7 3
HFE13 F / O7 10 0
aA1 and CGA correspond to STc10 and 69 of the Achtman MLST scheme,
respectively [16]. Within the B2 group, sub-groups I, II, IV, VI and IX correspond
to STc131, 73, 141, 12 and 95, respectively [16]. B2-UA = B2 unassignable using
our allele-specific assay [15].
TABLE 3. Comparison of clinical and microbiological char-
acteristics according to foetal death
Foetal death
p-valueNo n = 14 Yes n = 6
Clinical characteristics
Genital portal of entry 1 5 0.06
Empirical antibiotic inadequate n (%) 7 (50) 0 0.05
Bacterial characteristics
Resistance score, median (range) 1 (0–3) 1 (0–2) 0.5
Phylogroup n (%)
A 1 (7.1) 0 (0)
B2 12 (85.7) 4 (66.7) 1
D 1 (7.1) 2 (33.3)
Virulence score, median (range) 11 (4–12) 8 (6–10) 0.02
Virulence factor, n (%)
papC 10 (71.4) 1 (16.7) 0.04
papG 10 (71.4) 1 (16.7) 0.04
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high rate of foetal mortality (27%), confirming the poor foetal
outcome of bacteraemia during pregnancy [4]. Foetal mortality
was not due to inadequate antibiotherapy or related to a
specific clone or virulence factor. Paradoxically, strains asso-
ciated with foetal death exhibited a lower virulence score than
strains associated with no foetal death. In fact, the severity of
the disease is not linked to the intrinsic virulence of the strain
assessed by the number of virulence genes but, probably, to
host factors and the portal of entry. All foetal deaths except
one were associated with a genital portal of entry (p 0.06).
This result was non-significant but it might be due to a lack of
power. Indeed, chorioamnionitis often occurs on a particular
obstetrical background, such as cervical incompetence requir-
ing emergency cervical cerclage or in a context of preterm
prelabour rupture of the membranes. The only way to treat
clinically obvious chorioamnionitis in this case is to induce
delivery because antibiotics have a poor diffusion at the site of
infection in the case of chorioamnionitis. It could explain the
severity of genital tract bacteraemia for foetuses. Foetal death
is then related to a particular obstetrical background. Poor
outcome in non-urinary portal of entry bacteraemia has
already been shown in adults and children [13,19]. In the same
way, we have recently reported that in 60 E. coli strains
isolated from bacteraemic patients, a correlation was observed
between the number of virulence genes and the severity in a
mouse sepsis model but not with the severity in the patients
[20].
Strains causing bacteraemia overwhelmingly belonged to
phylogroup B2 (72%). Such a high proportion was only
observed in infants younger than 3 months with neonatal
meningitis or bacteraemia, in whom it reached more than 80%
[19,21–24]. In children older than 3 months and adults,
phylogroup B2 E. coli strains were isolated in 58% and 52%
of bacteraemia, respectively [13,19]. A clear decreasing trend
in the proportion of B2 phylogroup strains is thus observed in
bacteraemia from pregnant women and young infants com-
pared with older infants and adults. As compared with the
other groups, B2 phylogroup strains were shown in a mouse
model of sepsis to possess high intrinsic extra-intestinal
virulence. This property was linked to the presence of
numerous extra-intestinal virulence genes [12]. This indicates
that a high virulence potential is needed to induce extra-intes-
tinal infection in pregnant women and young infants, whereas
in older infants and adults, strains of other phylogroups can
cause the disease, probably as a result of the pathophysiology
of the disease underpinned by the host status and the portal of
entry [25]. This was not expected, as pregnancy induces
immunological variations that could increase susceptibility to
bacterial infection [26]. However, a recent study highlighted
variations of bactericidal activities of the genital tract secre-
tions during pregnancy compared with non-pregnant women
[27]. During pregnancy, there is an increase of bactericidal
activities and a decrease in E. coli colonization. Strains from the
B2 phylogroup seem to be better suited to colonizing the
vagina in particular if they possess more virulence factor genes
[28]. Accordingly, in our study, the median virulence score was
significantly higher in strains isolated from pregnant women
than in strains isolated from non-pregnant patients from the
COLIBAFI study (10 vs. 9, p 0.05) [13].
Among the B2 phylogroup, we observed a clear oligocl-
onality, with STc73 (subgroup II) and STc95 (subgroup IX)
representing more than half of the strains. In fact, these
lineages are also preeminent in various extra-intestinal
infections such as newborn meningitis [23], infant [19,24]
and adult bacteraemia [15,29] and urinary tract infections in
adults [29,30]. Interestingly, we also observed a high
proportion (19%) of STc12 (subgroup VI), which is not
frequent in adult infections but had been found to be
relatively frequent in a cohort of young infants with
bacteraemia [24]. This oligoclonality was also observed at
the O-type level with a predominance of O6 and O4 types.
Lastly, all but one D-group strain belonged to the clonal A
group (STc69) [31].
This study has several limitations. First, we pooled two
studies with different designs, but with the same data recorded
during the same time period. Second, strains were collected
before the spread of ESBL in the community [32]. Lastly, the
number of studied patients is rather low, leading to a small
power for most comparisons. However, this is the first study
focusing on clinical and microbiological E. coli bacteraemia in
pregnant women. We demonstrate that bacteraemia in
pregnant women is due to a few highly virulent clones but
TABLE 4. Comparison of urinary portal of entry bactera-
emia in pregnant women (‘Cases’) vs. non-pregnant women
(‘Controls’)
Cases
n = 15
Controls
n = 30 OR (IC 95%) p
p-value
(Fisher)
Type of infection
Community
acquired
11 (78.6) 23 (85.2) 1 – 0.7
Nosocomial 3 (21.4) 4 (14.8) 1.6 (0.2–20.5) 1
Empirical antibiotic
inadequate
No 5 (33.3) 6 (20) 1.9 (0.4–10.0) 0.5
Yes 10 (66.7) 24 (80) 1 –
Multidrug resistance
No 15 (100) 28 (93.3) 1 – 0.5
Yes 0 (0) 2 (6.7) – –
Phylogroup
A 1 (6.7) 0 (0) – – 0.7
B1 0 (0) 1 (3.3) – –
B2 11 (73.3) 23 (76.7) 1 –
D 3 (20) 6 (20) 1 (0.1–16.0) 1
Virulence score,
median (range)
10 (1–16) 12 (6–15) 0.9 (0.7–1.1) 0.4 0.5
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severity, represented by foetal death, is mainly related to the
genital portal of entry.
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